Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CA 2254121 A1 · Owner: Merck Frosst Canada Inc. · Inventors: Gottesdiener, Keith; Hancock, Bruno; Winters, Conrad
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 2.5 to 250 mgs of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone. The invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 2.5 to 250 mgs of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)furanone. The invention is also directed to the use of 5,5-dimethyl-3-(3fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 13, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 13, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 13, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.